articleTop 1% cited

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings

Archives of Ophthalmology · 2001 · Vol. 119(7) · pp. 969–969

Marie Diener‐West✉(Johns Hopkins University)John D. EarleShai FineBS Hawkins(Johns Hopkins University)Claudia S. MoySandra M. ReynoldsAndrew SchachatB. R. Straatsma

View via DOI Publisher page

Abstract

Mortality rates following 125I brachytherapy did not differ from mortality rates following enucleation for up to 12 years after treatment of patients with choroidal melanoma who enrolled in this COMS trial. The power of the study was sufficient to indicate that neither treatment is likely to increase or decrease mortality rates by as much as 25% relative to the other.

Ocular Oncology and Treatments Glaucoma and retinal disorders Ocular Infections and TreatmentsEnucleationMedicineBrachytherapyOcular MelanomaRandomized controlled trialSurgeryClinical trialMelanomaInternal medicineRadiation therapy

MeSH terms

AdultAgedAged, 80 and overBrachytherapyCanadaChoroid NeoplasmsEligibility DeterminationFemaleHumansIodine RadioisotopesMaleMelanomaMiddle AgedPostoperative ComplicationsUnited States

Citations

767

FWCI

28.51

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes